Literature DB >> 3009326

Effects of converting enzyme inhibition on split renal function in renovascular hypertension.

I Miyamori, S Yasuhara, Y Takeda, H Koshida, M Ikeda, K Nagai, H Okamoto, T Morise, R Takeda, T Aburano.   

Abstract

The effects of captopril on effective renal plasma flow and glomerular filtration rate were studied using a noninvasive radioisotopic method on individual kidneys in eight patients with renovascular hypertension and 12 patients with essential hypertension with various renin levels. Four patients with renovascular hypertension had unilateral while three had bilateral renal artery stenosis. The effective renal plasma flow and glomerular filtration rate were determined by using 131I-iodohippurate sodium and 99mTc-diethylenetriamine pentaacetic acid, respectively. Glomerular filtration rate and effective renal plasma flow were significantly reduced in the stenotic kidneys of patients with renovascular hypertension compared with values in nonstenotic kidneys (p less than 0.01). Treatment with captopril, 37.5 to 75 mg/day for 1 to 48 weeks, further reduced the glomerular filtration rate only in stenotic kidneys, and effective renal plasma flow increased in both kidney types. In two of the three renal hypertensive patients with bilateral renal artery stenosis, captopril produced a reversible azotemia that was unrelated to the fall in blood pressure, as evidenced by the lack of azotemia seen after a moderate blood pressure reduction induced by other antihypertensive medications. These results indicate that endogenous angiotensin II is essential in maintaining the glomerular filtration rate in stenotic kidneys and suggest that a reduction in glomerular filtration rate during captopril administration could indicate the presence of renal artery stenosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009326     DOI: 10.1161/01.hyp.8.5.415

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Effect of captopril in Takayasu's arteritis.

Authors:  C Saieh; H Amaral; B Morales
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 3.  ACE inhibitors in non-diabetic renal disease.

Authors:  R J Fluck; A E Raine
Journal:  Br Heart J       Date:  1994-09

Review 4.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Differences between 99mTc-DTPA and 99mTc-MAG3 captopril renographies in renovascular hypertension.

Authors:  K Itoh; Y Matsui; C Kato; T Mochizuki; A Kitabatake
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 6.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 7.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 8.  Diagnosis and treatment of renal artery stenosis.

Authors:  Pierre-François Plouin; Liesbeth Bax
Journal:  Nat Rev Nephrol       Date:  2010-01-26       Impact factor: 28.314

9.  The renal blood flow reserve in healthy humans and patients with atherosclerotic renovascular disease measured by positron emission tomography using [15O]H2O.

Authors:  Johanna Päivärinta; Niina Koivuviita; Vesa Oikonen; Hidehiro Iida; Kaisa Liukko; Ilkka Manner; Eliisa Löyttyniemi; Pirjo Nuutila; Kaj Metsärinne
Journal:  EJNMMI Res       Date:  2018-06-11       Impact factor: 3.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.